198 related articles for article (PubMed ID: 29774635)
21. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study.
Correll CU; Kohegyi E; Zhao C; Baker RA; McQuade R; Salzman PM; Sanchez R; Nyilas M; Carson W
J Am Acad Child Adolesc Psychiatry; 2017 Sep; 56(9):784-792. PubMed ID: 28838583
[TBL] [Abstract][Full Text] [Related]
22. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study.
Citrome L; Risinger R; Cutler AJ; Du Y; Zummo J; Nasrallah HA; Silverman BL
CNS Spectr; 2018 Aug; 23(4):284-290. PubMed ID: 28625204
[TBL] [Abstract][Full Text] [Related]
23. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
[TBL] [Abstract][Full Text] [Related]
24. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
[TBL] [Abstract][Full Text] [Related]
25. Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder.
Cantillon M; Prakash A; Alexander A; Ings R; Sweitzer D; Bhat L
Schizophr Res; 2017 Nov; 189():126-133. PubMed ID: 28215471
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.
Findling RL; McKenna K; Earley WR; Stankowski J; Pathak S
J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):327-42. PubMed ID: 23083020
[TBL] [Abstract][Full Text] [Related]
27. Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder.
Kamijima K; Kimura M; Kuwahara K; Kitayama Y; Tadori Y
Psychiatry Clin Neurosci; 2018 Aug; 72(8):591-601. PubMed ID: 29660207
[TBL] [Abstract][Full Text] [Related]
28. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial.
Durgam S; Cutler AJ; Lu K; Migliore R; Ruth A; Laszlovszky I; Németh G; Meltzer HY
J Clin Psychiatry; 2015 Dec; 76(12):e1574-82. PubMed ID: 26717533
[TBL] [Abstract][Full Text] [Related]
29. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.
Kane JM; Meltzer HY; Carson WH; McQuade RD; Marcus RN; Sanchez R;
J Clin Psychiatry; 2007 Feb; 68(2):213-23. PubMed ID: 17335319
[TBL] [Abstract][Full Text] [Related]
30. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
[TBL] [Abstract][Full Text] [Related]
31. A 40-week double-blind aripiprazole versus lithium follow-up of a 12-week acute phase study (total 52 weeks) in bipolar I disorder.
El-Mallakh RS; Marcus R; Baudelet C; McQuade R; Carson WH; Owen R
J Affect Disord; 2012 Feb; 136(3):258-66. PubMed ID: 22209190
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study.
Savitz A; Lane R; Nuamah I; Singh J; Hough D; Gopal S
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):548-57. PubMed ID: 26218669
[TBL] [Abstract][Full Text] [Related]
33. Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study.
Ishigooka J; Iwashita S; Tadori Y
Psychiatry Clin Neurosci; 2018 Jun; 72(6):445-453. PubMed ID: 29582518
[TBL] [Abstract][Full Text] [Related]
34. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
Ardizzone I; Nardecchia F; Marconi A; Carratelli TI; Ferrara M
Psychopharmacol Bull; 2010; 43(2):45-66. PubMed ID: 21052042
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study.
Xiao L; Zhao Q; Li AN; Sun J; Wu B; Wang L; Zhang H; Zhang R; Li K; Xu X; Liu T; Zhang W; Xie S; Xu X; Tan Y; Zhang K; Zhang H; Guan N; Xian M; Uki M; Wang G
Psychopharmacology (Berl); 2022 Jan; 239(1):243-251. PubMed ID: 34989824
[TBL] [Abstract][Full Text] [Related]
36. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study.
Findling RL; Correll CU; Nyilas M; Forbes RA; McQuade RD; Jin N; Ivanova S; Mankoski R; Carson WH; Carlson GA
Bipolar Disord; 2013 Mar; 15(2):138-49. PubMed ID: 23437959
[TBL] [Abstract][Full Text] [Related]
37. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.
Fleischhacker WW; McQuade RD; Marcus RN; Archibald D; Swanink R; Carson WH
Biol Psychiatry; 2009 Mar; 65(6):510-7. PubMed ID: 18986646
[TBL] [Abstract][Full Text] [Related]
38. Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.
Correll CU; Zhao J; Carson W; Marcus R; McQuade R; Forbes RA; Mankoski R
J Am Acad Child Adolesc Psychiatry; 2013 Jul; 52(7):689-698.e3. PubMed ID: 23800482
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
40. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
